Acción tecnológica

47. Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008; 115: S3-12.

48. Shaikh S and Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician 2002; 66: 1723-30.

49. Vafai A and Berger M. Zoster in patients infected with HIV: a review. Am J Med Sci 2001; 321: 372-80. 50. Marsh RJ and Cooper M. Ophthalmic herpes zoster. Eye (Lond) 1993; 7: 350-70.

51. Kaufman SC. Anterior segment complications of herpes zoster ophthalmicus. Ophthalmology 2008;

115: S24-32.

52. Richards JC, Maartens G and Davidse AJ. Course and complications of varicella zoster ophthalmicus in a high HIV seroprevalence population (Cape Town, South Africa). Eye (Lond) 2009; 23: 376-81. 53. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infec-

tion. J Infect Dis 1992; 166: 1153-6.

54. Bayu S and Alemayehu W. Clinical profile of herpes zoster ophthalmicus in Ethiopians. Clin Infect Dis 1997; 24: 1256-60.

55. Huygens A, Dauby N, Vermijlen D, et al. Immunity to cytomegalovirus in early life. Front Immunol 2014; 5: 552.

56. Sinclair J. Human cytomegalovirus: Latency and reactivation in the myeloid lineage. J Clin Virol 2008; 41: 180-5.

57. Lynn WA and Lightman S. The eye in systemic infection. Lancet 2004; 364: 1439-50.

58. Chee S, Bacsal K, Jap A, et al. Clinical features of cytomegalovirus anterior uveitis in immunocom- petent patients. Am J Ophthalmol 2008; 145: 834-40.

59. Kestelyn PG and Cunningham ET Jr. HIV/AIDS and blindness. Bull World Health Organ 2001; 79: 208-13.

60. Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthal-

mol 2010; 4: 285-99.

61. Ford N, Shubber Z, Saranchuk P, et al. Burden of HIV-related cytomegalovirus retinitis in resource- limited settings: A Systematic Review. Clin Infect Dis 2013; 57: 1351-61.

62. Pathai S, Gilbert C, Weiss HA, et al. Differing spectrum of HIV-associated ophthalmic disease among patients starting antiretroviral therapy in India and South Africa. Trop Med Int Health 2011; 16: 356-9.

63. Ubani UA. Bacteriology of external ocular infections in Aba, South Eastern Nigeria. Clin Exp Optom 2009; 92: 482-9.

64. Capriotti JA, Pelletier JS, Shah M, et al. The etiology of infectious corneal ulceration in Sierra Leone.

Int Ophthalmol 2010; 30: 637-40.

65. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.

66. Lawn SD and Zumla AI. Tuberculosis. Lancet 2011; 378: 57-72.

67. Gupta V, Gupta A and Rao NA. Intraocular tuberculosis – an update. Surv Ophthalmol 2007; 52: 561-87.

68. Basu S, Monira S, Modi RR, et al. Degree, duration, and causes of visual impairment in eyes affected with ocular tuberculosis. J Ophthalmic Inflamm Infect 2014; 4: 3.

69. Bodaghi B and LeHoang P. Ocular tuberculosis. Curr Opin Ophthalmol 2000; 11: 443-8.

70. Allan BD and Dart JK. Strategies for the management of microbial keratitis. Br J Ophthalmol 1995;

Chapter 1

32

71. De Groot-Mijnes JD, Rothova A, Van Loon AM, et al. Polymerase chain reaction and Goldmann- Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis. Am J Ophthal-

mol 2006; 141: 313-8.

72. Sharma S. Diagnosis of infectious diseases of the eye. Eye 2012; 26: 177-84.

73. Azari AA and Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. JAMA 2013;

310: 1721-9.

74. Margolis R, Brasil OF, Lowder CY, et al. Vitrectomy for the diagnosis and management of uveitis of unknown cause. Ophthalmology 2007; 114: 1893-7.

75. Lobo A and Lightman S. Vitreous aspiration needle tap in the diagnosis of intraocular inflamma- tion. Ophthalmology 2003; 110: 595-9.

76. Taravati P, Lam D and Van Gelder RN. Role of molecular diagnostics in ocular microbiology. Curr

Ophthalmol Rep 2013; 1.

77. Kaye SB, Baker K and Bonshek R. Human herpesviruses in the cornea. Br J Ophthalmol 2000; 84: 563-71.

78. Panda A, Pal Singh T, Satpathy G, et al. Comparison of polymerase chain reaction and standard microbiological techniques in presumed bacterial corneal ulcers. Int Ophthalmol 2015; 35: 159-65. 79. Zhao G, Zhai H, Yuan Q, et al. Rapid and sensitive diagnosis of fungal keratitis with direct PCR

without template DNA extraction. Clin Microbiol Infect 2014; 20: 776-82.

80. Schaftenaar E, Lecuona K, Baarsma S, et al. Anterior chamber paracentesis to improve diagnosis and treatment of infectious uveitis in South Africa. S Afr Med J 2015; 105: 628-30.

81. Kijlstra A. The value of laboratory testing in uveitis. Eye (Lond) 1990; 4: 732-6.

82. Teoh SC and Dick AD. Diagnostic techniques for inflammatory eye disease: past, present and future: a review. BMC Ophthalmol 2013; 13: 41.

83. Wade NK. Diagnostic testing in patients with ocular inflammation. Int Ophthalmol Clin 2000; 40: 37-54.

84. Freed EO and Martin MA. HIVs and Their Replication. In: Knipe DM, Howley PM, Griffin DE, et al., eds. Fields Virology. 5th ed. Vol. 2. Philadelphia: Lippincott-Williams and Wilkins, 2007: 2479-99. 85. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fact sheet 2015. Geneva: UNAIDS; 2015. 86. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDSinfo. Available at: http://aidsinfo.

unaids.org/.

87. Simon V, Ho DD and Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treat- ment. Lancet 2006; 368: 489-504.

88. Volberding PA and Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010;

376: 49-62.

89. Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortal- ity of HIV-infected individuals. AIDS 2010; 24: 123-37.

90. Department of Health, Republic of South Africa. The South African antiretroviral treatment guide- lines 2013. Department of Health, Republic of South Africa, Pretoria, 2013.

91. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treat- ment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012;

7: e33948.

92. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.

93. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 2013; 10: e1001418.

33